Addex Therapeutics Ltd (ADXN)
$8.00 $0.05 (0.63%) 4:38 PM 12/13/24
NASDAQ | $USD | BiotechnologyStock Data
-
Market Cap
$8.71M -
Day's Range
$7.95 - $8.40 -
Volume
55,028 -
52 Week Low / High
$5.00 - $27.90 -
PE Ratio
- -
PEG Ratio
- -
Dividend Frequency
-
- Capital Growth
- Dividend Return to Date
- Dividend Payout year Est.
- Expenses
- Total Return
- Total Return %
- 0
- Strong Buy
- 1
- Buy
- 0
- Hold
- 0
- Sell
- 0
- Strong Sell
- $29.99
- Target Price
Company News
-
Addex Therapeutics Ltd (ADXN) Q2 2024 Earnings Call Transcript Highlights: Key Financials and ... — Oct 1st, 2024
Series A Financing: USD 63 million led by Perceptive Advisors. Equity Interest in Neurosterix: CHF 5 million and a 20% equity interest. Milestone Payments: Up to $330 million from Indivior for GABAB PAM program. Revenue: CHF 0.1 million in Q2 2024, down from CHF 0.6 million in Q2 2023. R&D...
-
Addex Therapeutics Ltd (ADXN) Q2 2024 Earnings Call Transcript Highlights: Key Financials and ... — Oct 1st, 2024
Series A Financing: USD 63 million led by Perceptive Advisors. Equity Interest in Neurosterix: CHF 5 million and a 20% equity interest. Milestone Payments: Up to $330 million from Indivior for GABAB PAM program. Revenue: CHF 0.1 million in Q2 2024, down from CHF 0.6 million in Q2 2023. R&D...
-
Addex Therapeutics Ltd (ADXN) Q2 2024 Earnings Call Transcript Highlights: Key Financials and ... — Oct 1st, 2024
Series A Financing: USD 63 million led by Perceptive Advisors. Equity Interest in Neurosterix: CHF 5 million and a 20% equity interest. Milestone Payments: Up to $330 million from Indivior for GABAB PAM program. Revenue: CHF 0.1 million in Q2 2024, down from CHF 0.6 million in Q2 2023. R&D...
-
Addex Therapeutics Ltd (ADXN) Q2 2024 Earnings Call Transcript Highlights: Key Financials and ... — Oct 1st, 2024
Series A Financing: USD 63 million led by Perceptive Advisors. Equity Interest in Neurosterix: CHF 5 million and a 20% equity interest. Milestone Payments: Up to $330 million from Indivior for GABAB PAM program. Revenue: CHF 0.1 million in Q2 2024, down from CHF 0.6 million in Q2 2023. R&D...
-
Addex Therapeutics Ltd (ADXN) Q2 2024 Earnings Call Transcript Highlights: Key Financials and ... — Oct 1st, 2024
Series A Financing: USD 63 million led by Perceptive Advisors. Equity Interest in Neurosterix: CHF 5 million and a 20% equity interest. Milestone Payments: Up to $330 million from Indivior for GABAB PAM program. Revenue: CHF 0.1 million in Q2 2024, down from CHF 0.6 million in Q2 2023. R&D...
-
Addex Therapeutics Ltd (ADXN) Q2 2024 Earnings Call Transcript Highlights: Key Financials and ... — Oct 1st, 2024
Series A Financing: USD 63 million led by Perceptive Advisors. Equity Interest in Neurosterix: CHF 5 million and a 20% equity interest. Milestone Payments: Up to $330 million from Indivior for GABAB PAM program. Revenue: CHF 0.1 million in Q2 2024, down from CHF 0.6 million in Q2 2023. R&D...
-
Addex Therapeutics Ltd (ADXN) Q2 2024 Earnings Call Transcript Highlights: Key Financials and ... — Oct 1st, 2024
Series A Financing: USD 63 million led by Perceptive Advisors. Equity Interest in Neurosterix: CHF 5 million and a 20% equity interest. Milestone Payments: Up to $330 million from Indivior for GABAB PAM program. Revenue: CHF 0.1 million in Q2 2024, down from CHF 0.6 million in Q2 2023. R&D...
-
Addex Therapeutics Ltd (ADXN) Q2 2024 Earnings Call Transcript Highlights: Key Financials and ... — Oct 1st, 2024
Series A Financing: USD 63 million led by Perceptive Advisors. Equity Interest in Neurosterix: CHF 5 million and a 20% equity interest. Milestone Payments: Up to $330 million from Indivior for GABAB PAM program. Revenue: CHF 0.1 million in Q2 2024, down from CHF 0.6 million in Q2 2023. R&D...
Similar Stocks
Portfolio
Comprised of 1 portfolios